ERK/MAP kinase signaling has been implicated in brain development, long-term memory, and in the response to antidepressants. Conditional
Braf knockout mice enabled us to unravel a new role of ERK/MAPK signaling for emotional behavior. Braf
icko/juvenile and Braf
cko mutants, that complete
Braf inactivation in principle forebrain neurons by the age of 4 or 6 weeks respectively, exhibited decreased anxiety-like behavior in the LD and EPM. We focused the further analysis of the mutant's phenotype on the hippocampus since this region has been shown to play an important role in emotional processing
[35]–
[37].
Since inhibitory GABAergic neurotransmission is a key modifier of anxiety, the anxiolytic phenotype of Braf
cko mice might have been caused by an increased release of GABA or an enhanced response of GABA
A receptors. A direct negative regulation of GABA
A receptors by ERK mediated phosphorylation has been demonstrated
in vitro for the α1 subunit
[29]. However, the analysis of GABAergic neurotransmission revealed the normal function of this system in the hippocampus of Braf
cko mice and does not explain their anxiolytic phenotype. A major function of ERK/MAPK signaling is the regulation of gene expression by the activation of the transcription factors CREB1 and ELK1. Gene expression analysis in the hippocampus of Braf
cko mutants revealed numerous up- or downregulated transcripts that could account for the behavioral and morphological phenotypes of these mutants. To identify the direct transcriptional targets of neuronal ERK/MAPK signaling, we analyzed the promoter regions of all differentially downregulated transcripts for the presence of CREB1 and ELK1 binding motifs. This analysis revealed an evolutionary conserved group of nine transcripts that can be regarded as the core of ERK/MAPK responsive genes in hippocampal neurons. Besides the immediate early genes
Egr1/
Egr4 and the regulatory phosphatases
Dusp4/
Dusp6, which are known targets of MAPK signaling, we identified five genes that were previously unrecognized as ERK/MAPK targets. Three of these genes, early growth response 1 (
Egr1), somatostatin (
Sst), and brain-derived neurotrophic factor (
Bdnf, transcript 3), are of particular interest since they play a role in neuronal activity and behavioral modification. Mutant mice with a complete depletion of the transcription factor
Egr1 show a strong anxiolytic phenotype in the elevated plus maze
[38]. In
Braf mutants, that exhibit reduced levels of
Egr1 mRNA, a similar effect was found in the two anxiety-related behavior tests. The somatostatin system subserves neuromodulatory roles in the brain, influencing motor activity, sleep, sensory processes, and cognitive functions.
Sst expression has been found altered in bipolar disorder
[39] and shown to control the migration of developing neurons
[40]. A deficiency of mature BDNF and its receptor TrkB has been implicated in increased anxiety-related behavior and decreased neuronal complexity of hippocampal neurons
[31],
[41]. In Braf
cko mice, we observed a reduction of the
Bdnf transcript variant 3 that initiates at the
Bdnf promoter IV. This promoter was shown to be an initial target in the therapeutic action of the mood stabilizers lithium and valproic acid
[42]. Furthermore, ERK/MAPK signaling has been found
in vitro to act as positive regulator of dendritogenesis
[43] and reduced neuronal complexity is also found in
Bdnf and
TrkB mutants. These mutants, however, exhibit increased anxiety behavior
[31],
[41]. In future studies it would be therefore interesting to further study the role of BDNF in mediating emotional behavior in
Braf mutants and to investigate whether
Braf mutants are still sensitive to antidepressant treatment or whether the loss of ERK/MAPK signaling and subsequent
Bdnf inactivation prevent their action.
Finally, Mozhui et al.
[44] found a correlation between stress-induced alterations in anxiety-related behavior and the Grin2a NMDA receptor, a known upstream activator of the ERK/MAPK pathway, which was accompanied by an overlap in gene expression alterations.
It is therefore possible that the reduced expression of these “core" genes and their downstream targets cause the altered anxiety behavior, but also the reduced neuronal complexity and the fragmented activity during the sleep period of Braf
cko mice. However, at present we cannot attribute the action of individual regulated genes directly to specific phenotypes of Braf
cko mice. As shown for
C. elegans, ERK/MAPK controlled biological phenotypes are mediated by functional groups of 2–10 interacting proteins
[45].
The fragmented activity pattern of Braf
cko mice and their increased activity during the resting phase may represent a disturbance of sleep, e.g. a delayed sleep onset. Since the disruption of sleep and circadian activity are associated with psychiatric disorders
[46] it will be interesting to further study the sleeping behavior of
Braf mutants and to investigate in inducible Braf
icko mice whether the fragmented activity phenotype results from developmental effects. Despite the alterations in gene expression, neuronal morphology, and reduced anxiety, Braf
cko mice exhibited normal depression-like behavior as measured by the FST and TST paradigms that are used to assess behavioral despair
[47].
The influences of developmental gene knockouts on anxiety-related behavior have been widely discussed
[48], and the early postnatal period has been found critical for the development of neural circuits that mediate anxiety and suggest the neurodevelopmental origin of anxiety disorders
[49]. Using inducible 5-HT
1AR deficient mice, it has been shown that adults exhibit increased anxiety if 5-HT
1AR is absent during the third and fourth postnatal week, but not if it is absent in the adult brain
[50]. During the postnatal period, the hippocampal neurocircuitry is rapidly maturing. For example, the development of basal and apical dendrites is achieved during the first to fourth week of life
[51]. In addition, the formation of axonal terminals and dendritic spines in the hippocampal CA1 region is not completed before day 24
[52]. Since
Braf becomes inactivated in Braf
cko mice 2–6 weeks after birth, we asked whether the anxiolytic phenotype of these mutants originates from postnatal developmental alterations. We compared inducible mutants that underwent
Braf inactivation either in the early postnatal development or the adult brain. We found that the anxiolytic phenotype occurred only in
Braf mutants that were induced at 3 weeks but not at the age of 9 weeks. This result suggests that a juvenile ERK/MAPK deficiency in forebrain principle neurons leads to long-lasting neurodevelopmental alterations that cause reduced anxiety in adults, providing further evidence for the postnatal period as critical for the establishment of normal anxiety behavior. As found for 5-HT
1AR
[50], in the adult brain ERK/MAPK signaling is not directly linked to anxiety. Therefore, it will be of interest to further study whether the anxiolytic phenotype of juvenile
Braf mutants may be linked to alterations in serotonergic neurotransmission. In contrast to Braf
icko/juvenile and Braf
cko mice, Braf
icko/adult mutants exhibited reduced activity in the FST, suggesting that in the adult brain, ERK/MAPK signaling plays a role in the modulation of depression-like behavior. This finding is consistent with previous observations that associated ERK/MAPK signaling with depression-like behavior in adult mice and rats. Treatment of mice with the MEK inhibitor PD184161 increases depression-like behavior
[13] whereas an increase of ERK/MAPK signaling was found upon treatment with the mood stabilizers lithium
[14],
[15] and valproic acid
[15],
[16]. In addition, it has been recently described that depressive subjects exhibit an increased activity of the MAPK phosphatase MKP-1 and that MKP-1 overactivity causes depressive behaviors in rodents
[53]. Our results confirm the direct relationship of ERK/MAPK signaling and depression-like behavior but restrict this relation to the adult brain. The functional redirection of ERK/MAPK signaling may be mediated by distinct sets of activator and effector molecules that transduce different signals in the juvenile
versus the adult brain. The ERK/MAPK pathway is known to be activated during embryogenesis by fibroblast growth factor receptors (FGFR)
[54], while in the adult brain CRH receptor 1 and glucocorticoid receptor were shown to activate ERK
[55],
[56]. All of these receptors have been implicated in the modification of anxiety- and depression-like behavior, but further studies are required to define which of these receptors, or other receptors, are coupled to the ERK/MAPK pathway in the juvenile brain.
Our study is the first reporting a role of neuronal ERK/MAPK signaling for anxiety-like behavior in juvenile brain development and for depression-like behavior in the adult brain. The latter finding confirms that ERK/MAPK signaling is essential for the expression of normal behavior in the FST. Therefore, the MAP kinase phosphatases MKP-2, -3, -4, or -6, which mediate negative feedback inhibition of ERK kinases
[57], may represent new targets for the development of antidepressive drugs. Given the effect of ERK/MAPK on emotional behavior, the genes that constitute this pathway could also play a role in the etiology of mental disorders. Our results suggest that alleles for
Braf and other members of the ERK/MAPK pathway may represent risk factors for the development of psychiatric diseases, either by copy number variations in affected genotypes
[58] or by altered epigenetic control of gene expression.
Besides the Braf
cko and Braf
icko/juvenile mutants, various knockout mouse models exhibit reduced adult anxiety-like behavior, like conditional mutants for
Crhr1 or the glucocorticoid receptor
Nr3c1 gene
[59],
[60]. Since gene inactivation in these models occurs before or during juvenile brain development by the use of noninducible Cre driver lines, it is possible that phenotypes reported from such early postnatal mutants represent developmental alterations and do not report the functional role of these genes in the adult brain.
Our results provide the first demonstration that an inducible, Cre/loxP-based conditional mutant allows to differentiate between gene function in the juvenile and adult brain. The future application of inducible gene inactivation in the brain is greatly facilitated by the International Knockout Mouse Consortium (IKMC,
www.knockoutmouse.org) that provides Cre/loxP conditional alleles in ES cells and mice on a genome-wide scale. Moreover, since knockout mice are also used for the validation of drug targets
[61], inducible gene inactivation could allow a better prediction of the action of future drugs in the adult brain. Our results from Braf
icko mice show that inducible gene inactivation faithfully reports on gene function in the adult brain and provides a valuable tool to study the genetic basis of psychiatric diseases.